clorgyline has been researched along with Parkinson Disease in 15 studies
Clorgyline: An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.
clorgyline : An aromatic ether that is the 2,4-dichlorophenyl ether of 3-aminopropan-1-ol in which the nitrogen is substituted by a methyl group and a prop-1-yn-3-yl group. A monoamine oxidase inhibitor, it was formerly used as an antidepressant.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Administration in daily dosage of 10 mgs produces an almost complete inhibition of the enzyme." | 2.37 | R-(-)-deprenyl and parkinsonism. ( Yahr, MD, 1987) |
| "Parkinson disease is characterized by a major loss (approximately 80% or more) of dopaminergic nigrostriatal neurons and by an increased turnover of neurotransmitter by surviving neurons of the nigrostriatal tract." | 1.28 | Dopamine turnover and glutathione oxidation: implications for Parkinson disease. ( Cohen, G; Spina, MB, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (40.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Distinto, S | 1 |
| Yáñez, M | 1 |
| Alcaro, S | 2 |
| Cardia, MC | 1 |
| Gaspari, M | 1 |
| Sanna, ML | 1 |
| Meleddu, R | 1 |
| Ortuso, F | 2 |
| Kirchmair, J | 1 |
| Markt, P | 1 |
| Bolasco, A | 1 |
| Wolber, G | 1 |
| Secci, D | 2 |
| Maccioni, E | 1 |
| Rojas, RJ | 1 |
| Edmondson, DE | 1 |
| Almos, T | 1 |
| Scott, R | 1 |
| Massari, ME | 1 |
| Carradori, S | 1 |
| Petzer, A | 2 |
| Bagetta, D | 1 |
| De Monte, C | 1 |
| De Vita, D | 1 |
| Guglielmi, P | 1 |
| Zengin, G | 1 |
| Aktumsek, A | 1 |
| Petzer, JP | 2 |
| Yeon, SK | 1 |
| Choi, JW | 1 |
| Park, JH | 1 |
| Lee, YR | 1 |
| Kim, HJ | 1 |
| Shin, SJ | 1 |
| Jang, BK | 1 |
| Kim, S | 1 |
| Bahn, YS | 1 |
| Han, G | 1 |
| Lee, YS | 1 |
| Pae, AN | 1 |
| Park, KD | 1 |
| Meiring, L | 1 |
| Legoabe, LJ | 1 |
| Dell'Antone, P | 1 |
| IbnLkayat, M | 1 |
| Drago, D | 1 |
| Zatta, P | 1 |
| Sandler, M | 1 |
| Youdim, MB | 2 |
| Finberg, JP | 1 |
| Wang, J | 1 |
| Goldstein, DS | 1 |
| Kopin, IJ | 1 |
| Bankiewicz, KS | 1 |
| Liptrot, J | 1 |
| Holdup, D | 1 |
| Phillipson, O | 1 |
| Brannan, T | 1 |
| Prikhojan, A | 1 |
| Martínez-Tica, J | 1 |
| Yahr, MD | 2 |
| Holzbauer, M | 1 |
| Knoll, J | 1 |
| Spina, MB | 1 |
| Cohen, G | 1 |
3 reviews available for clorgyline and Parkinson Disease
| Article | Year |
|---|---|
Are there MAO inhibitors specific for dopamine metabolism?
Topics: Animals; Binding Sites; Brain; Clorgyline; Dopamine; Drug Synergism; Humans; In Vitro Techniques; Le | 1977 |
On the dual nature of monoamine oxidase.
Topics: Animals; Antidepressive Agents; Binding Sites; Brain; Catecholamines; Clorgyline; Dose-Response Rela | 1978 |
R-(-)-deprenyl and parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Benserazide; Clorgyline; Dopamine; Drug Therapy, Combi | 1987 |
12 other studies available for clorgyline and Parkinson Disease
| Article | Year |
|---|---|
Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.
Topics: Binding Sites; Humans; Hydrazones; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Dyn | 2012 |
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Small Molecule Libraries | 2015 |
Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.
Topics: Acetylcholinesterase; Animals; Antioxidants; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose- | 2018 |
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzene Derivatives; Disease Models, Animal; | 2018 |
The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
Topics: Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Propy | 2022 |
Acidic vesicles of the endo-exocytic pathways as targets for some anti-monoamine oxidase drugs.
Topics: Acid-Base Equilibrium; Acids; Alzheimer Disease; Amantadine; Animals; Brain; Brain Chemistry; Brain | 2009 |
Monoamine oxidase inhibitors and their pharmacological significance.
Topics: Animals; Antidepressive Agents; Brain; Clorgyline; Humans; Monoamine Oxidase; Monoamine Oxidase Inhi | 1983 |
Biochemical characterization of the active site of brain monoamine oxidase.
Topics: Antidepressive Agents; Binding Sites; Brain; Clorgyline; Humans; Mitochondria; Monoamine Oxidase; Mo | 1980 |
Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dialysis; Dopamine; Homovanill | 1995 |
1,2,3,4-Tetrahydro-2-methyl-4,6,7-isoquinolinetriol inhibits tyrosine hydroxylase activity in rat striatal synaptosomes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biopterins; Chromatography, High Pressure Liq | 1994 |
In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dopamine; Homovanillic Acid; L | 1995 |
Dopamine turnover and glutathione oxidation: implications for Parkinson disease.
Topics: Animals; Cerebral Cortex; Clorgyline; Corpus Striatum; Disease Models, Animal; Dopamine; Glutathione | 1989 |